P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846440.48761.8d |
| _version_ | 1827336835513188352 |
|---|---|
| author | A. Bobin S. Manier J. De Keizer L. Karlin A. Perrot C. Hulin D. Caillot C. Mariette P. Lenain V. Richez M. Tiab C. Touzeau A. Jaccard O. Decaux C. Araujo K. Belhadj L. Benboubker C. Déal M. Macro L. Vincent B. Arnulf B. Bareau T. Braun C. Calmettes D. mamoun H. Zerazhi H. Demarquette P. Feugier C. Fohrer-sonntag S. Godet M.-O. Petillon H. Avet-Loiseau X. Leleu |
| author_facet | A. Bobin S. Manier J. De Keizer L. Karlin A. Perrot C. Hulin D. Caillot C. Mariette P. Lenain V. Richez M. Tiab C. Touzeau A. Jaccard O. Decaux C. Araujo K. Belhadj L. Benboubker C. Déal M. Macro L. Vincent B. Arnulf B. Bareau T. Braun C. Calmettes D. mamoun H. Zerazhi H. Demarquette P. Feugier C. Fohrer-sonntag S. Godet M.-O. Petillon H. Avet-Loiseau X. Leleu |
| author_sort | A. Bobin |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:15Z |
| format | Article |
| id | doaj.art-25f030c23657427bb2e8a33dc9168aca |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:15Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-25f030c23657427bb2e8a33dc9168aca2024-03-02T03:51:54ZengWileyHemaSphere2572-92412022-06-01678378410.1097/01.HS9.0000846440.48761.8d202206003-00783P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01A. Bobin0S. Manier1J. De Keizer2L. Karlin3A. Perrot4C. Hulin5D. Caillot6C. Mariette7P. Lenain8V. Richez9M. Tiab10C. Touzeau11A. Jaccard12O. Decaux13C. Araujo14K. Belhadj15L. Benboubker16C. Déal17M. Macro18L. Vincent19B. Arnulf20B. Bareau21T. Braun22C. Calmettes23D. mamoun24H. Zerazhi25H. Demarquette26P. Feugier27C. Fohrer-sonntag28S. Godet29M.-O. Petillon30H. Avet-Loiseau31X. Leleu321 CHU de Poitiers, Poitiers2 chu de lille, lille1 CHU de Poitiers, Poitiers3 CHU de Lyon, Lyon4 CHU de Toulouse, Toulouse5 CHU de Bordeaux, Bordeaux6 CHU de Dijon, Dijon7 CHU de Grenoble, Grenoble8 CHU de Rouen, Rouen9 CHU de Nice, Nice10 CH la Roche sur Yon, La Roche Sur Yon11 CHU de Nantes, Nantes12 CHU de Limoges, Limoges13 CHU de Rennes, Rennes14 CH de Bayonne, Bayonne15 CHU de Créteil-APHP, Créteil16 CHU de Tours, Tours17 Intergroupe Francophone du Myélome, Paris18 CHU de Caen, Caen19 CHU de Montpellier, Montpellier20 Hopital Saint Louis, Paris21 Hopital Privé Sevigne, Cesson Sevigne22 Hopital Avicenne, Bobigny23 CH de Périgueux, Périgueux24 CHU de Angers, Angers25 CH de Avignon, Avignon26 CH de Dunkerque, Dunkerque27 CHRU de Nancy, Nancy28 CHU de Strasbourg, Strasbourg29 CHU de Reims, Reims, France2 chu de lille, lille4 CHU de Toulouse, Toulouse1 CHU de Poitiers, Poitiershttp://journals.lww.com/10.1097/01.HS9.0000846440.48761.8d |
| spellingShingle | A. Bobin S. Manier J. De Keizer L. Karlin A. Perrot C. Hulin D. Caillot C. Mariette P. Lenain V. Richez M. Tiab C. Touzeau A. Jaccard O. Decaux C. Araujo K. Belhadj L. Benboubker C. Déal M. Macro L. Vincent B. Arnulf B. Bareau T. Braun C. Calmettes D. mamoun H. Zerazhi H. Demarquette P. Feugier C. Fohrer-sonntag S. Godet M.-O. Petillon H. Avet-Loiseau X. Leleu P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 HemaSphere |
| title | P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 |
| title_full | P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 |
| title_fullStr | P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 |
| title_full_unstemmed | P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 |
| title_short | P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 |
| title_sort | p891 ixazomib pomalidomide and dexamethasone ixpd in relapsed or refractory multiple myeloma rrmm characterized with high risk cytogenetics ifm 2014 01 |
| url | http://journals.lww.com/10.1097/01.HS9.0000846440.48761.8d |
| work_keys_str_mv | AT abobin p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT smanier p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT jdekeizer p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT lkarlin p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT aperrot p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT chulin p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT dcaillot p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT cmariette p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT plenain p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT vrichez p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT mtiab p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT ctouzeau p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT ajaccard p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT odecaux p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT caraujo p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT kbelhadj p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT lbenboubker p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT cdeal p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT mmacro p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT lvincent p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT barnulf p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT bbareau p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT tbraun p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT ccalmettes p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT dmamoun p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT hzerazhi p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT hdemarquette p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT pfeugier p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT cfohrersonntag p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT sgodet p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT mopetillon p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT havetloiseau p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 AT xleleu p891ixazomibpomalidomideanddexamethasoneixpdinrelapsedorrefractorymultiplemyelomarrmmcharacterizedwithhighriskcytogeneticsifm201401 |